Jiajie Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiajie Cao has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Xinyue Zhang
Department of Stomatology, Shengjing Hospital of China Medical University, Shenyang, China
2 shared publications - Zhi-Ming Wang
Department of Stomatology, Shengjing Hospital of China Medical University, Shenyang, PR China
2 shared publications
Latest Publications
- 1 February 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (3) , 1368
Correction to: Effectiveness comparisons of antiviral treatments for Bell palsy: a systematic review and network meta-analysis
- 1 February 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (3) , 1368
Correction to: Effectiveness comparisons of antiviral treatments for Bell palsy: a systematic review and network meta-analysis
- 5 March 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (3) , 1353-1367
Effectiveness comparisons of antiviral treatments for Bell palsy: a systematic review and network meta-analysis
Objectives Antiviral treatments for Bell palsy have been widely used, but there is no definite conclusion of which is the most effective antiviral drug. We conducted a systematic review of randomized controlled trials (RCTs) including network meta-analysis to investigate the comparative effectiveness of antiviral treatments for Bell palsy. Data RCTs comparing effectiveness between antiviral treatments and placebo were included. Risk of bias within and across studies was assessed with the Cochrane tool and the GRADE approach, respectively. Random-effects pairwise meta-analyses were conducted, followed by network meta-analysis. Sources Three electronic databases were searched from inception to May 18, 2020. Study selection 11 trials and 3393 patients with four arms and eleven contrasts were included. Results Significant differences were observed between placebo and famciclovir with respect to overall recovery and no statistically significant differences were found from other comparisons. Treatment ranking based on the evidence network indicated that famciclovir shared the best results, followed by valacyclovir, acyclovir, and finally placebo. Adverse events of famciclovir were too rare and slight to be analyzed. Our confidence in pairwise comparisons was moderate to low, due to study limitations, inconsistency, and imprecision; our confidence in ranking was moderate, due to study limitations. Inconsistency is not deemed to exist by a loop-specific approach and node-splitting procedure. Results of exploring publication bias are satisfying. Conclusions According to pairwise and network comparisons, famciclovir could be better than placebo and the effectiveness of other antiviral treatments are similar. For clinical efficacy, famciclovir obtains the best recovery rate of facial function for Bell palsy. Acyclovir has the lowest rate of synkinesis, though, it is not adequately recommended and more superior trails are needed in the future.
- 5 March 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (3) , 1353-1367
Effectiveness comparisons of antiviral treatments for Bell palsy: a systematic review and network meta-analysis
Objectives Antiviral treatments for Bell palsy have been widely used, but there is no definite conclusion of which is the most effective antiviral drug. We conducted a systematic review of randomized controlled trials (RCTs) including network meta-analysis to investigate the comparative effectiveness of antiviral treatments for Bell palsy. Data RCTs comparing effectiveness between antiviral treatments and placebo were included. Risk of bias within and across studies was assessed with the Cochrane tool and the GRADE approach, respectively. Random-effects pairwise meta-analyses were conducted, followed by network meta-analysis. Sources Three electronic databases were searched from inception to May 18, 2020. Study selection 11 trials and 3393 patients with four arms and eleven contrasts were included. Results Significant differences were observed between placebo and famciclovir with respect to overall recovery and no statistically significant differences were found from other comparisons. Treatment ranking based on the evidence network indicated that famciclovir shared the best results, followed by valacyclovir, acyclovir, and finally placebo. Adverse events of famciclovir were too rare and slight to be analyzed. Our confidence in pairwise comparisons was moderate to low, due to study limitations, inconsistency, and imprecision; our confidence in ranking was moderate, due to study limitations. Inconsistency is not deemed to exist by a loop-specific approach and node-splitting procedure. Results of exploring publication bias are satisfying. Conclusions According to pairwise and network comparisons, famciclovir could be better than placebo and the effectiveness of other antiviral treatments are similar. For clinical efficacy, famciclovir obtains the best recovery rate of facial function for Bell palsy. Acyclovir has the lowest rate of synkinesis, though, it is not adequately recommended and more superior trails are needed in the future.